Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro C-terminal sequence for metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank is approved in Russia as an anxiolytic with nootropic properties. Research demonstrates that Selank modulates GABAergic neurotransmission, enhances enkephalin expression, regulates immune function, and provides anxiolytic effects without the sedation or dependence associated with benzodiazepines.
Tuftsin Origin and Peptide Design
Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) released from the Fc domain of IgG immunoglobulin by splenic enzymes. It functions as an immunostimulant, promoting phagocytosis, antigen presentation, and natural killer cell activity. The Selank team recognized that tuftsin fragments also exhibited CNS activity and engineered Selank by appending the Pro-Gly-Pro tripeptide to the C-terminus—the same stabilizing modification used in Semax.
The Pro-Gly-Pro extension increases the peptide’s resistance to aminopeptidase degradation, extending its functional half-life from minutes (for tuftsin) to several hours (for Selank). This modification is based on the glyproline sequence found naturally in collagen and known to confer protease resistance. The resulting heptapeptide retains tuftsin’s immunomodulatory properties while gaining enhanced anxiolytic and nootropic CNS effects.
GABAergic Mechanisms
Selank’s anxiolytic effects are primarily mediated through modulation of the GABAergic system—the brain’s primary inhibitory neurotransmitter network. Research demonstrates that Selank enhances GABA-A receptor sensitivity without directly binding the benzodiazepine site. The peptide increases GABA concentration in the synaptic cleft by modulating GABA transaminase activity and enhancing GABA release from presynaptic terminals.
Unlike benzodiazepines, Selank does not produce tolerance, physical dependence, or withdrawal upon discontinuation in animal studies. This is because its mechanism involves allosteric modulation and GABA system optimization rather than direct agonism at the benzodiazepine binding site. The practical implication is anxiolytic activity without the sedation, cognitive impairment, and addiction liability associated with benzodiazepine pharmacology.
Enkephalin and Opioid Modulation
Selank significantly increases the expression of enkephalins—endogenous opioid peptides involved in pain modulation, mood regulation, and stress response. Specifically, Selank upregulates proenkephalin (PENK) gene expression in the hippocampus and prefrontal cortex. Enkephalins act on delta-opioid receptors to produce anxiolytic and antidepressant effects. This enkephalinergic mechanism provides a second anxiolytic pathway complementary to GABAergic modulation.
The opioid modulation by Selank does not produce euphoria, respiratory depression, or dependence typical of mu-opioid receptor agonists, because enkephalins preferentially activate delta-opioid receptors with different downstream signaling characteristics. This selectivity contributes to Selank’s favorable safety profile in anxiolytic applications.
Immunomodulatory Properties
Retaining its tuftsin heritage, Selank exhibits immunomodulatory effects that are unusual for a CNS-active peptide. The peptide enhances innate immune function by promoting monocyte and macrophage phagocytic activity, increasing natural killer cell cytotoxicity, and modulating cytokine expression. In viral infection models, Selank increased interferons and IL-6 while decreasing excessive TNF-alpha production.
This dual anxiolytic-immunomodulatory profile is relevant because psychological stress and anxiety are well-documented immunosuppressants. Selank may address both the psychological and immunological consequences of chronic stress through integrated mechanisms.
Clinical Evidence
Russian clinical trials evaluated Selank in patients with generalized anxiety disorder (GAD). Intranasal Selank at doses of 250-750 mcg daily demonstrated statistically significant reductions in anxiety scores (Hamilton Anxiety Rating Scale) compared to placebo over 14-28 day treatment periods. The anxiolytic effect was comparable to benzodiazepines but without sedation, psychomotor impairment, or rebound anxiety upon discontinuation.
Additional clinical studies examined Selank in patients with anxiety comorbid with neurasthenia and in patients with adjustment disorders. Across studies, Selank showed consistent anxiolytic effects with an onset within the first week of treatment and sustained benefit throughout the treatment period.
Nootropic Effects
Beyond anxiolysis, Selank demonstrates nootropic properties in both animal models and human studies. The peptide enhances memory consolidation in passive avoidance tasks and spatial memory in maze paradigms. Cognitive benefits are attributed to enhanced hippocampal function through BDNF modulation, improved cholinergic transmission, and reduced anxiety-related interference with cognitive processing.
Frequently Asked Questions
What is Selank?
Selank is a synthetic heptapeptide based on tuftsin with a Pro-Gly-Pro stabilizing extension, approved in Russia as an anxiolytic and nootropic. It modulates GABAergic signaling and immune function.
How does Selank differ from Semax?
Semax is ACTH-derived with primary effects on neurotrophic factors and cognition. Selank is tuftsin-derived with primary effects on anxiety, GABAergic signaling, and immune modulation.
Is Selank approved for medical use?
Yes, in Russia for generalized anxiety disorder and anxiety with neurasthenia, administered intranasally. It is not FDA or EMA approved.